Herpes Labialis (Oral Herpes) (Infectious Disease) - Drugs in Development, 2021

October 2021 | 61 pages | ID: HBFAF0446595EN
Global Markets Direct

Abstracts

Herpes Labialis (Oral Herpes) (Infectious Disease) - Drugs in Development, 2021

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Herpes Labialis - Drugs In Development, 2021, provides an overview of the Herpes Labialis (Infectious Disease) pipeline landscape.Oral herpes is an infection of the lips, mouth, or gums due to the herpes simplex virus. Oral herpes is also called herpes labialis. Symptoms include sore throat, fever, swollen glands and painful swallowing. Treatment includes antiviral medications.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Herpes Labialis - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Herpes Labialis (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.The Herpes Labialis (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Herpes Labialis (Oral Herpes) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies/Universities/Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 3, 2, 6 and 1 respectively.

Herpes Labialis (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

• The pipeline guide provides a snapshot of the global therapeutic landscape of Herpes Labialis (Infectious Disease).
• The pipeline guide reviews pipeline therapeutics for Herpes Labialis (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
• The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
• The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
• The pipeline guide reviews key companies involved in Herpes Labialis (Infectious Disease) therapeutics and enlists all their major and minor projects.
• The pipeline guide evaluates Herpes Labialis (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
• The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
• The pipeline guide reviews latest news related to pipeline therapeutics for Herpes Labialis (Infectious Disease)

REASONS TO BUY

• Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
• Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
• Find and recognize significant and varied types of therapeutics under development for Herpes Labialis (Infectious Disease).
• Classify potential new clients or partners in the target demographic.
• Develop tactical initiatives by understanding the focus areas of leading companies.
• Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
• Formulate corrective measures for pipeline projects by understanding Herpes Labialis (Infectious Disease) pipeline depth and focus of Indication therapeutics.
• Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
• Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction
Global Markets Direct Report Coverage
Herpes Labialis (Oral Herpes) - Overview
Herpes Labialis (Oral Herpes) - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Herpes Labialis (Oral Herpes) - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Herpes Labialis (Oral Herpes) - Companies Involved in Therapeutics Development
AiCuris AG
Astellas Pharma Inc
Brandenburg Antiinfektiva GmbH
Dobecure SL
Heidelberg Immunotherapeutics Gmbh
Jupiter Wellness Inc
NanoViricides Inc
Provention Bio Inc
Rational Vaccines Inc
Shulov Innovative Science Ltd
Vironova Medical AB
Herpes Labialis (Oral Herpes) - Drug Profiles
amenamevir - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Aspidasept - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
B-220 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ethamsylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HDIT-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
JW-400 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
NVHHV-101 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pritelivir - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PRV-300 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RVX-101HSV1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule for Herpes Labialis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZEP-3 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZEP-4 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Herpes Labialis (Oral Herpes) - Dormant Projects
Herpes Labialis (Oral Herpes) - Discontinued Products
Herpes Labialis (Oral Herpes) - Product Development Milestones
Featured News & Press Releases
Aug 23, 2017: AiCuris Announces Final Patient Treated in Clinical Phase 2 Trial with Topical Pritelivir for the Treatment of recurrent Labial Herpes
Dec 01, 2016: AiCuris Announces Start of LipP 1: First Subject Enrolled in the Clinical Phase 2 Trial with Topical Pritelivir for the Treatment of recurrent Labial Herpes
Nov 05, 2010: AiCuris To Present Preclinical And Phase I Data Of Anti-HSV Drug AIC316 At Antivirals Congress
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Herpes Labialis (Oral Herpes), 2021
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Number of Products by Stage and Target, 2021
Number of Products by Stage and Mechanism of Action, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Herpes Labialis (Oral Herpes) - Pipeline by AiCuris AG, 2021
Herpes Labialis (Oral Herpes) - Pipeline by Astellas Pharma Inc, 2021
Herpes Labialis (Oral Herpes) - Pipeline by Brandenburg Antiinfektiva GmbH, 2021
Herpes Labialis (Oral Herpes) - Pipeline by Dobecure SL, 2021
Herpes Labialis (Oral Herpes) - Pipeline by Heidelberg Immunotherapeutics Gmbh, 2021
Herpes Labialis (Oral Herpes) - Pipeline by Jupiter Wellness Inc, 2021
Herpes Labialis (Oral Herpes) - Pipeline by NanoViricides Inc, 2021
Herpes Labialis (Oral Herpes) - Pipeline by Provention Bio Inc, 2021
Herpes Labialis (Oral Herpes) - Pipeline by Rational Vaccines Inc, 2021
Herpes Labialis (Oral Herpes) - Pipeline by Shulov Innovative Science Ltd, 2021
Herpes Labialis (Oral Herpes) - Pipeline by Vironova Medical AB, 2021
Herpes Labialis (Oral Herpes) - Dormant Projects, 2021
Herpes Labialis (Oral Herpes) - Discontinued Products, 2021

List Of Figures

LIST OF FIGURES

Number of Products under Development for Herpes Labialis (Oral Herpes), 2021
Number of Products under Development by Companies, 2021
Number of Products by Targets, 2021
Number of Products by Stage and Targets, 2021
Number of Products by Mechanism of Actions, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021